ArticleCureus2025
Seizure Following Zolpidem Withdrawal in a Patient Presenting as a Stroke Lysis Call: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke lysis, or thrombolysis, is a time-sensitive intervention for acute ischemic stroke, but careful distinction from stroke mimics is essential to avoid inappropriate treatment. Zolpidem, a non-benzodiazepine hypnotic, is generally regarded as having low dependence potential; however, prolonged or high-dose use can result in withdrawal syndromes, including seizures. We report the case of a 46-year-old woman presenting with acute left upper limb weakness and facial sensory changes, initially managed as a stroke lysis call. She was outside the lysis window and had initial negative neuroimaging. Within 24 hours, she developed recurrent generalized seizures requiring intravenous lorazepam. Subsequent collateral history revealed chronic high-dose zolpidem use (50-200 mg daily), discontinued abruptly, confirming a diagnosis of zolpidem withdrawal seizure. The patient was successfully treated with a benzodiazepine taper and discharged with community mental health and substance misuse follow-up. This case emphasizes the importance of thorough medication history-taking in stroke evaluations, as withdrawal syndromes can closely mimic acute cerebrovascular events. It is also interesting to note that zolpidem can increase the risk of strokes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.